Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center today announced efforts to advance its capabilities to seamlessly connect basic science, translational and clinical research data for the benefit of patients through a technology collaboration with Syntropy and the Foundry platform. This initiative is part of MD Anderson’s new Strategy aimed at focusing its mission to end cancer on approaches that maximize the impact on humanity, which includes growing its capabilities in data science.
Building upon the institution’s substantial digital infrastructure, the Foundry platform adds to MD Anderson’s growing ability to contextually integrate and draw clinically meaningful insights from vast quantities of data, including clinical, biospecimen, imaging, and other sources, while assuring appropriate use and data protections through state-of-the-art provenance and access controls. By assembling and harmonizing the diverse data types and making them “similar” enough to analyze while highlighting their unique differences, MD Anderson researchers are able to more effectively find data, establish collaborations and team together to efficiently derive insights.
“MD Anderson has a significant opportunity and a responsibility to our many stakeholders to create a digital ecosystem that promotes collaboration and advances scientific discovery to enhance patient outcomes,” said David Jaffray, Ph.D., chief technology and digital officer at MD Anderson. “Through our ongoing focus on enabling the use of new technologies to place quantitative data in context for our researchers, we foster cutting-edge oncology data science to inform our cancer discovery research and to accelerate translation of our research findings into benefits for cancer patients.”
As an example, hundreds of collaborators across diverse disciplines at MD Anderson already have conducted more than 50 projects in Foundry, with an initial focus on COVID-19 and its impact on cancer patients. Recognizing an urgent need to rapidly address research questions at the start of the pandemic, MD Anderson enabled its researchers to leverage the Foundry platform to generate insights from a common, curated, readily available source of aggregated COVID-19 data for cancer patients. Research from this work will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting in June.
“We are well-positioned to maximize our understanding of the massive amount of largely unstructured data in cancer care and research,” said Scott Woodman, M.D., Ph.D., associate professor of Genomic Medicine at MD Anderson. “The technology has enabled multiple researchers, including my own research team and me, to extract insights and to efficiently generate learnings aimed at enhancing patients’ lives.”
Through ongoing education and implementation efforts, MD Anderson will be conducting a strategic and systematic rollout to additional researchers on the platform and expanding access throughout the institution. Additional opportunities exist to explore secure data collaborations with other academic and industry partners. MD Anderson also has submitted grant proposals using Foundry as an enabling platform for collaboration.
“The ability of our technology to reduce the time it takes to aggregate and harmonize disparate and often unstructured data sets, all within a highly secure infrastructure, is critical for a mission-driven institution like MD Anderson,” said James Kugler, director at Syntropy. “This work has allowed researchers to focus on what they do best – generating insights – and has created a foundation to enable transformative collaborations with the ultimate goal of accelerating discoveries for all cancer patients.”
Breakthroughs in cancer care, enabled by new technological advances and computational advances, will occur more quickly by breaking down silos, by harmonizing data and by allowing for collaborations that increase the opportunity for bench-to-bedside research. MD Anderson’s future-focused data strategy provides for the use of data within the shared context of clinical care, biomedical research and world-leading expertise, protected by an enterprise focus on data governance that prioritizes both collaboration and security.
“We are on the verge of a new era in which both the culture and technology of collaboration are aligning and the potential to accelerate progress is unimaginable,” Jaffray said. “Patients are counting on MD Anderson, and we are committed to fulfilling our mission.”
- 30 -
About MD Anderson The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 50 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990, and has ranked first 15 times in the last 18 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
Syntropy is a technology company specializing in healthcare data governance, harmonization, and collaboration solutions aimed at unlocking the value of real-world data. Syntropy empowers health care providers, researchers, and collaborators to derive insights from every point of data they collect and generate in a secure, compliant, and ethical manner. Syntropy is a partnership between EMD Digital Inc., a subsidiary of Merck KGaA, Darmstadt, Germany (DAX:MKGAF), and Palantir Technologies Inc. (NYSE:PLTR). Foundry is a licensed trademark of Palantir. Syntropy is headquartered in Cambridge, MA.